
How to Prevent and Treat Hair Loss
Check in With Your Dermatologist
A doctor will help you narrow down which type of hair loss you're dealing with. 'More than 50 percent of the time, we can nail the diagnosis based on the patient's health history and examining the scalp and hair,' says Angela Lamb, a New York-based dermatologist. From there, you can discuss whether medications make sense for you. Minoxidil, a topical or oral treatment, is often the first line of defense for androgenetic alopecia hair loss (caused by aging, genetics and hormones), while telogen effluvium (brought on by stressors like sickness or a life change) are typically resolved by managing your triggers.
Get Your Scalp in Shape
For most types of hair loss and thinning, proper care starts at the scalp. These are some of the most effective professional and at-home treatments that can help with issues like inflammation or irritation:
Platelet-rich plasma therapy involves a medical professional injecting a concentrated version of your own blood into your scalp, to potentially stimulate dormant follicles. PRP tends to be best for androgenetic alopecia, says Lamb, but can sometimes also speed up recovery from stress-related hair loss.
Near-infrared lasers can reduce inflammation and spur activity in the follicles, slowing hair loss and improving hair quality after a few months. You can use either a head cap or a hand-held comb at home two to three times a week for eight to 20 minutes per session. Consistency is key with these devices, and the Boston-based dermatologist Maryanne Makredes Senna notes that combs are easier to maneuver. F.D.A.-approved models include Hairmax's Ultima Classic LaserComb and Theradome's Pro LH80.
Microneedling the scalp triggers a wound-healing response, which can encourage hair growth. It also enhances the absorption of other ingredients like minoxidil or PRP. Though you can find at-home microneedling tools (such as dermarollers or dermapens), the professional-level devices used by dermatologists have longer needles for better results.
Whether or not you try in-office therapies, practice good scalp care: Don't overwash your hair (one to three times a week is generally best, depending on your hair type), go light with styling products at your roots to avoid buildup and run any major changes to your scalp health (such as redness, flakes or irritation) by your doctor.
Be Cautious of Supplements
Certain deficiencies — such as in vitamin D, iron and protein — can stunt hair growth. But before stocking up on supplements, talk to your doctor; most adults can get adequate nutrients through their diet or a daily multivitamin, according to Lamb. Be wary of ultra-potent supplements marketed specifically for hair loss, which are unregulated and potentially harmful. 'High doses of biotin can disrupt thyroid levels, for example, and high doses of B vitamins can cause acne,' says Lamb. Focus instead on reducing stress and chronic inflammation, common triggers that, if left unchecked, can accelerate hair loss.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille


Time Business News
14 hours ago
- Time Business News
BrainSim-X Launches Developer Platform for Neural Simulation Data
BrainSim-X announced the launch of a developer access program that allows researchers and app developers to integrate brain simulation data into their applications. More information about the platform is available at their official website . The Bangalore-based research initiative said the platform will focus on medical applications, particularly epilepsy research and neurological treatment development. Unlike typical API services, BrainSim-X requires developers to submit applications explaining their intended use cases before gaining access to the platform. Interested developers can request API credentials through their secure portal. The approval process takes approximately one week, with the organization reviewing each application to ensure it aligns with their medical research focus. One developer who has used the platform for three months described it as providing detailed neural activity data that requires significant technical expertise to implement properly. A detailed account of this developer's experience can be found in their comprehensive review . 'The platform generates large amounts of data that require powerful computing resources,' the developer said. 'It's designed for serious medical research rather than general app development.' The organization provides documentation and support for developers working on brain-computer interfaces, neuroscience research projects, and medical applications. Their research findings are available for review in published papers. Real-time data access became available recently, allowing developers to integrate live neural simulation feeds into their applications. The platform is intended for researchers studying brain activity patterns, testing neurological treatments, and developing diagnostic tools. BrainSim-X operates the service through a secure API that provides access to neural simulation data generated by their brain modeling platform. Technical requirements include high-memory computing systems capable of processing large neural datasets. Additional technical insights about the platform's capabilities can be found in this technical analysis . The research initiative says the developer program represents part of their commitment to making brain simulation technology accessible to the global research community. Applications are evaluated based on their potential contribution to medical research and neurological treatment development. BrainSim-X has not disclosed revenue generated from the developer platform, stating that funds support ongoing research activities. The organization expects demand for the platform to grow as more researchers learn about neural simulation applications in medical research. Future platform updates will include enhanced simulation capabilities and additional tools for analyzing neural activity patterns. BrainSim-X says the developer program differentiates it from commercial AI companies by focusing on open research collaboration rather than proprietary technology development. The platform supports research into cognitive enhancement, educational technology, and advanced diagnostic systems. Developers interested in accessing the platform must demonstrate relevant research experience and explain how they plan to use neural simulation data in their projects. BrainSim-X provides training resources to help developers understand neuroscience concepts necessary for effectively using the platform. The organization says it will continue expanding the developer program while maintaining focus on medical and scientific applications. Related Resources TIME BUSINESS NEWS

Associated Press
15 hours ago
- Associated Press
Major Health Insurers Slash Prior Authorization Requirements, Transforming the PA Technology Landscape
Black Book Research identifies Cohere Health, Innovaccer, and Waystar among leading vendors rapidly adapting to new industry rules. NEW YORK CITY, NY / ACCESS Newswire / July 26, 2025 / U.S. healthcare is undergoing a pivotal shift as major insurers-led by UnitedHealthcare and Humana-begin to significantly reduce or eliminate prior authorization (PA) requirements for hundreds of routine procedures. Accelerated by federal policy, provider frustration, and consumer demands for timely access to care, these sweeping changes signal a new era in PA technology and operations, according to a July 2025 flash survey conducted by Black Book Research. Industry Drivers: Regulatory Action Meets Provider and Consumer Pressure Insurers covering over 250 million Americans have committed to streamlining or removing PA burdens by the end of 2026. This is partly driven by the Centers for Medicare & Medicaid Services (CMS), which is launching a pilot program in six states in January 2026 requiring faster, more transparent prior authorizations for select Medicare services. CMS has also announced national response time standards for Medicare Advantage plans, further intensifying the need for automation and interoperability in PA processes. Key Survey Insights from the Field Black Book Research's flash survey compiled viewpoints from: 24 IT leaders representing the top 10 PA vendors; 108 managed care and health plan IT and operational decision-makers; 142 healthcare providers and administrative leaders; and 100 healthcare consumers with recent PA experiences. Notable Findings: 84% of managed care executives support reducing PA requirements 96% of healthcare providers report improved workflows and lower administrative burdens 99% of consumers favor eliminating PA for routine care; 83% say they've experienced harmful care delays 67% of health plans expect to reevaluate or end contracts with existing PA vendors by 2026 Additional Observations: 90% of providers foresee broad adoption of interoperable PA tools by 2027 94% of payers plan substantial investment in AI-based PA platforms 100% of consumers prefer providers with automated and transparent PA processes 96% of PA vendor executives acknowledge their current solutions require modernization within two years __________ Vendors Rapidly Adapting and Leading the Innovation Curve: Client Top KPI Scores Black Book highlights the top-performing vendors already making critical advancements to align with industry shifts: Cohere Health - Excels in AI-based automation, payer-provider integration, and CMS-aligned interoperability Innovaccer - Offers strong EHR integration and regulatory compliance dashboards for PA workflows Waystar - Enhancing its Auth Accelerate platform for real-time eligibility checks and exception handling ScribeRunner - Developing dynamic auto-approval rulesets and real-time tracking modules CoverMyMeds - Expanding AI-powered real-time authorizations for both pharmacy and medical benefits Change Healthcare - Transitioning legacy infrastructure with modular FHIR APIs for automated decision-making Availity - Driving advanced API adoption and digital submission channels PriorAuthNow (Rhyme) - Connecting providers and payers through real-time electronic submission with limited manual effort Black Book's Q1-Q2 client satisfaction rankings show these vendors excelled across 18 qualitative KPIs for PA technology. Cohere Health earned the highest overall honors, with MCG Health, eviCore Healthcare, Agadia, Infinx, and Availity also receiving good marks. Onyx led in FHIR-based PA platform innovation. Detailed competitive intelligence reports are available in the Black Book research store. __________ Vendors Facing Existential Threats in the New Era Not all companies are poised for success. Several previously top-rated PA vendors now face considerable risk due to outdated systems and slow adaptability: eviCore Healthcare - Still dependent on manual review processes, with limited AI capabilities HealthHelp (WNS) - Lagging behind in interoperability and modern payer integration PriorAuthNow (Rhyme) - Despite innovation efforts, struggles with scalable real-time API integration threaten its long-term viability _________ Looking Ahead: A Positive Outlook for Adaptive Vendors While legacy vendors must evolve rapidly or risk market exit, the broader outlook for PA tech is optimistic. Companies investing in automated, intelligent, and interoperable systems are well-positioned to thrive. 'The future of prior authorization is transparent, automated, and fully integrated into clinical workflows,' said Doug Brown, Founder of Black Book Research. 'Vendors delivering real-time, AI-powered solutions will define the next generation of care access efficiency for providers, payers, and patients alike.' About Black Book Research Black Book Research is a leading healthcare IT research firm known for its independent, vendor-agnostic approach. Over the past 15 years, Black Book has collected over 3 million survey responses from nearly 500,000 healthcare professionals. The firm's flash surveys and long-form evaluations provide real-time, unbiased insights that support strategic decision-making across the healthcare ecosystem. Visit or contact [email protected] for full survey results and vendor-specific performance details. Contact InformationPress Office 8008637590 SOURCE: Black Book Research press release